Citi rates ResMed Inc (RMD) as a Buy - The broker notes that although the shares have struggled hard on the resurfacing of competitive bidding concerns, the...

Citi rates ResMed Inc (RMD) as a Buy - The broker notes that although the shares have struggled hard on the resurfacing of competitive bidding concerns, the reaction is largely overdone and current levels are presenting a great buying opportunity. Citi believes the current situation will also offer a valuable opportunity for the company to return excess capital via the current buyback, which is already highly EPS and value-accretive. The price target is $5.79 (current price $4.82) with FY14 PER looking cheap at 15x. However, Citi notes significant upside risk to its forecasts if falls in the AUD continue.


2 topics

Livewire News brings you a wide range of financial insights with a focus on Global Macro, Fixed Income, Currencies and Commodities.

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.